丁丙诺啡镇痛对急性创伤救治中阿片负荷与临床轨迹的影响
该单中心观察性研究纳入2021年1月至2024年6月收治的成人创伤患者,创伤服务于2023年6月正式引入丁丙诺啡镇痛。非调整前后分析显示,丁丙诺啡使用增加与吗啡毫克当量(MME)降低(中位数138 vs 75,P<0.001;IRR 0.70,95%CI 0.69-0.71)、ICU入住率降低(IRR 0.78,95%CI 0.73-0.83)及ICU住院时间缩短(IRR 0.87,95%CI 0.80-0.94)相关。倾向性评分1:1匹配后(n=544),丁丙诺啡组ICU入住率更低(IRR 0.63,95%CI 0.54-0.73)、ICU住院时间更短(IRR 0.67,95%CI 0.59-0.75),中位MME无差异(114 vs 91,P=0.187),但IRR分析显示阿片暴露更低(IRR 0.82,95%CI 0.81-0.83)。各分析中生存与不良事件均无差异。
要点
- 非调整前后分析:丁丙诺啡使用增加与MME中位数降低相关(前138 vs 后75,P<0.001;IRR 0.70,95%CI 0.69-0.71)。
- 匹配后丁丙诺啡组ICU入住率更低(IRR 0.63,95%CI 0.54-0.73),ICU住院时间更短(IRR 0.67,95%CI 0.59-0.75)。
- 匹配后中位MME无差异(丁丙诺啡组114 vs 未用组91,P=0.187),但IRR分析显示阿片暴露更低(IRR 0.82,95%CI 0.81-0.83)。
- 各分析中生存与不良事件无差异。
- 舌下/颊黏膜与肠外丁丙诺啡分别按30和100的MME转换因子计算。
适用人群与场景
- 2021年1月至2024年6月收治于一级创伤中心的成人创伤患者。
- 匹配队列为2023年6月后收治、接受(Bup+)或未接受(Bup-)丁丙诺啡的患者,按人口学与损伤特征1:1最近邻倾向性评分匹配。
处置流程与药物剂量
- 舌下/颊黏膜丁丙诺啡按MME转换因子30计算,肠外丁丙诺啡按MME转换因子100计算。
研究设计与关键结果
- 研究类型:单中心观察性研究;非调整分析纳入3935例(前BΔ 2777例,后BΔ 1158例)。
- 非调整分析:丁丙诺啡使用增加与MME中位数降低相关(前138 vs 后75,P<0.001;IRR 0.70,95%CI 0.69-0.71)、ICU入住率降低(IRR 0.78,95%CI 0.73-0.83)、ICU住院时间缩短(IRR 0.87,95%CI 0.80-0.94)。
- 匹配后队列(n=544):丁丙诺啡组ICU入住率更低(IRR 0.63,95%CI 0.54-0.73),ICU住院时间更短(IRR 0.67,95%CI 0.59-0.75)。
- 匹配后中位MME无差异(丁丙诺啡组114 vs 未用组91,P=0.187),但IRR分析显示阿片暴露更低(IRR 0.82,95%CI 0.81-0.83)。
- 各分析中生存与不良事件无差异。
证据类型、等级与局限
- 证据类型:单中心观察性研究;证据等级:治疗/护理管理,Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在成人创伤患者中,丁丙诺啡镇痛与住院阿片暴露减少及ICU升级减少相关。
- 作者认为,进一步验证可能确立丁丙诺啡作为脆弱创伤人群阿片管理进步的的地位。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Schedule II opioids are widely used for trauma analgesia but carry dose-dependent risks of respiratory depression, tolerance, hyperalgesia, and addiction. Buprenorphine, a Schedule III opioid, is a potent analgesic with a more favorable safety profile; however, its integration into trauma care remains uncharacterized.
METHODS: A single-center observational study included adult trauma patients admitted to a Level I trauma center from January 2021 to June 2024. The trauma service formalized buprenorphine analgesia in June 2023. Outcomes were assessed by (1) an unadjusted pre/post June 2023 analysis (pre-BΔ vs. post-BΔ) and (2) a 1:1 nearest-neighbor propensity score-matched comparison of post-BΔ patients who received (Bup + ) or did not receive (Bup - ) buprenorphine. Bup + and Bup - groups were matched by demographics and injury characteristics. Sublingual/buccal and parenteral buprenorphine were assigned morphine milligram equivalents (MME) conversion factors of 30 and 100, respectively. Incidence rate ratios (IRRs) with 95% CI were calculated; significance was set at p <0.05.
RESULTS: Unadjusted analysis included 3,935 patients (2,777 pre-BΔ; 1,158 post-BΔ). Increased buprenorphine use was associated with reduced MME (median, 138 pre-BΔ vs. 75 post-BΔ; p < 0.001; IRR, 0.70; 95% CI, 0.69-0.71), lower intensive care unit (ICU) admission rates (IRR, 0.78; 95% CI, 0.73-0.83), and shortened ICU length of stay (IRR, 0.87; 95% CI, 0.80-0.94). In the matched post-BΔ cohort (n = 544) buprenorphine use was associated with lower ICU admission (IRR, 0.63; 95% CI, 0.54-0.73) and shorter ICU length of stay (IRR, 0.67; 95% CI, 0.59-0.75); median MME did not differ (114 vs. 91, p = 0.187), though IRR analyses demonstrated lower opioid exposure (IRR, 0.82; 95% CI, 0.81-0.83). Across analyses, no differences were observed in survival or adverse events.
CONCLUSIONS: In trauma patients, Schedule III buprenorphine analgesia was associated with reduced inpatient opioid exposure and ICU escalation. Further validation may establish buprenorphine as an advance in opioid stewardship for vulnerable trauma populations.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Conde-Yassin S, Gillen J, Stodghill J, et al. Buprenorphine analgesia: Impacts on opioid burden and clinical trajectory in acute trauma care. J Trauma Acute Care Surg. 2026. PMID: 42283437. doi:10.1097/TA.0000000000005084
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。